BUSINESS

• Daiichi Sankyo Seeks RA Indication for Pralia
  September 26, 2016

• Takeda, France’s Affilogic Join Hands on CNS Drugs
  September 23, 2016

• Takeda Ties Up with India’s Zydus Cadila for Chikungunya Vaccine
  September 23, 2016

• Maruho Gets Japan Rights to Dermira’s Hyperhidrosis Treatment
  September 23, 2016

• Sumitomo Dainippon’s ADHD Drug Meets Primary Endpoint in US PII/III Study in Children
  September 23, 2016

• Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
  September 21, 2016

• In a Turnaround, EU Panel Backs Takeda’s Ninlaro for Conditional Approval
  September 21, 2016

• Entyvio Shows Favorable Benefits in Both TNF-Naïve, TNF-Failed UC Patients
  September 21, 2016

• Meiji Seika Pharma to Establish Medical Science Promotion Office in October
  September 21, 2016

• Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
  September 21, 2016

• Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
  September 20, 2016

• Ono, NCC Join Hands for Discovery of Anticancer Agents, Biomarker Research
  September 20, 2016

• Osaka Univ. Spinoff, Sumitomo Dainippon Ink Joint Research Pact on Antibody-Inducing Peptides
  September 20, 2016

• MSD, Kyorin to Copromote Nasonex Nasal Spray
  September 16, 2016

• Asahi Kasei Pharma Gets Japan Rights to Basilea’s Antifungal Agent
  September 16, 2016

• Lenvatinib Gets EU Nod for RCC: Eisai
  September 16, 2016

• Sawai, Tatsumi Kagaku Tie Up on Kipres Generics
  September 16, 2016

• Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
  September 14, 2016

• Takeda Returns Rights to MacroGenics’ RA Candidate MGD010
  September 14, 2016

• Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
  September 14, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 457
• 458
• 459
• 460
• 461
• 462
• 463
• 464
• 465
• …
• Next ›
• 最終 »